Trial reportJournal of substance abuse treatment2018
Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Trial report in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Interventions for female drug-using offenders.The Cochrane database of systematic reviews · 2019Pooled it
- Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.PLoS medicine · 2019Pooled it
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature.Journal of addictions nursingPooled it
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2023Trial
- Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.Addiction science & clinical practice · 2023Trial
- Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.Journal of substance abuse treatment · 2022Trial
- Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.Substance abuse · 2021Trial
- Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018Trial
- Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia.Journal of community psychology · 2024Article
- Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.JAMA network open · 2024Article
- Community-based substance use treatment programs for reentering justice-involved adults: A scoping review.Drug and alcohol dependence reports · 2024Article
- Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.JAMA network open · 2023Article
- Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data.Journal of substance use and addiction treatment · 2023Article
- Medications for opioid use disorder during incarceration and post-release outcomes.Health & justice · 2023Article
- Midazolam, methamphetamine, morphine and nicotine intake in high-drinking-in-the-dark mice.Addiction biology · 2022Article
- Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell systematic reviews · 2022Article
- Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD.Health & justice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOpioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose. Initiation of extended release injectable naltrexone (XR-NTX)) prior to prison release might decrease relapse among opioid-dependent persons.
objectiveThis pilot study examined the feasibility and acceptability of XR-NTX injection prior to prison release among adult inmates with opioid use disorder, followed by six months of community XR-NTX treatment. It sought to determine effects on treatment retention and abstinence compared to post-release XR-NTX initiation.
methodsRecruitment for the study took place at the RIDOC's Adult Correctional Institute (ACI). Volunteers with a history of opioid dependence and a release date scheduled within 1-2months were self-referred in response to recruitment fliers. Consented volunteers were randomized to XR-NTX treatment prior to release followed by 5 monthly treatments in the community (pre-release) or six XR-NTX treatments in the community (post-release).
resultsOf 26 volunteers consented, 15 were randomized (9 pre-release, 6 post-release). The pre-release group generally had better treatment retention: 100% received the first NTX injection (vs. 67% post-release), 78% received more than one injection (vs. 17%) and 22% received all 6 injections (vs. 0%). The pre-release group also had greater abstinence, with a higher proportion of self-reported opioid free days in the first month after release (83% vs. 46%, fewer positive urine drug tests in the 6months after release (22% vs. 33%), and more days of opioid receptor blockade during the first two weeks after release, a high risk time for overdose death.
conclusionsInitiation of XR-NTX injection prior to release from prison might be an effective approach to reduce relapse to opioids, but these findings require confirmation in a larger trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.